STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLXN
  4. [Form 4] Silexion Therapeutics Corp Insider Trading Activity

Silexion (SLXN) CSO gets 49,726-share RSU grant, updates holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Shirvan Mitchell reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp chief scientific and development officer Shirvan Mitchell received a grant of 49,726 fully vested restricted share units that were immediately settled into ordinary shares at no cost, for his services as an officer and approved by the board. Following this award, his direct holdings total 50,707 ordinary shares, and he also directly holds stock options covering 478 ordinary shares, which are reported here for informational purposes only. The share and option amounts reflect prior 1-for-9 and 1-for-15 reverse share splits effective in late 2024 and mid‑2025.

Positive

  • None.

Negative

  • None.
Insider Shirvan Mitchell
Role CSO and CDO
Type Security Shares Price Value
Grant/Award Ordinary Shares 49,726 $0.00 --
holding Stock Option (right to buy Ordinary Shares) -- -- --
Holdings After Transaction: Ordinary Shares — 50,707 shares (Direct); Stock Option (right to buy Ordinary Shares) — 478 shares (Direct)
Footnotes (1)
  1. The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shirvan Mitchell
(Last) (First) (Middle)
C/O SILEXION THERAPEUTICS CORP
12 ABBA HILLEL ROAD
(Street)
RAMAT GAN L3 5250606
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CSO and CDO
3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 02/20/2026 A(2) 49,726 A $0 50,707 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy Ordinary Shares)(3) $907.71(4) 08/15/2024 06/07/2032 Ordinary Shares 478(4) 478 D
Explanation of Responses:
1. The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.
2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
4. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
/s/ Mirit Horenshtein Hadar, Attorney-in-fact 02/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Silexion Therapeutics (SLXN) report for Shirvan Mitchell?

Silexion reported that CSO and CDO Shirvan Mitchell received 49,726 fully vested restricted share units, immediately settled into ordinary shares. The grant was provided as compensation for his services as an officer and approved by the company’s board of directors.

How many Silexion (SLXN) ordinary shares does Shirvan Mitchell own after this Form 4?

After the reported grant, Shirvan Mitchell directly holds 50,707 Silexion ordinary shares. This total reflects adjustments for the company’s 1-for-9 and 1-for-15 reverse share splits completed in November 2024 and July 2025, as described in the filing footnotes.

What is the nature of the 49,726-share award to Silexion’s CSO/CDO?

The 49,726-share award consists of fully vested restricted share units that were immediately settled into underlying ordinary shares. It represents a grant, award, or other acquisition for Shirvan Mitchell’s officer services, with the issuance specifically approved by Silexion’s board of directors.

Were any stock option transactions for Silexion (SLXN) reported in this Form 4?

The Form 4 lists stock options representing 478 underlying ordinary shares held directly by Shirvan Mitchell, but notes no transactions in these options. The holdings are included for informational purposes only and have been adjusted for the company’s prior reverse share splits.

How did Silexion’s reverse share splits affect the holdings in this Form 4?

The filing explains that both ordinary share and option figures reflect a 1-for-9 reverse split on November 29, 2024, and a 1-for-15 reverse split on July 29, 2025. These corporate actions adjusted previously reported amounts to the current share and option levels.

Did Shirvan Mitchell pay anything for the 49,726 Silexion shares he received?

No cash consideration is indicated for the 49,726-share grant, which is reported at a price per share of $0.0000. The award represents fully vested restricted share units granted as part of his officer compensation and immediately settled into ordinary shares.